Trial reportBMJ open2022
Prostate MRI versus PSA screening for prostate cancer detection (the MVP Study): a randomised clinical trial.
Trial report in BMJ open, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02799303 (A Randomized Clinical Trial Comparing the Efficacy of MRI Versus PSA for Prostate Cancer Screening), which is not on this map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Randomized Clinical Trial Comparing the Efficacy of MRI Versus PSA for Prostate Cancer Screening: The MVP Study (MRI vs PSA)
Who cites it
33 citing papers in PubMed, 47 citations in OpenAlex.
- Exploring motivations and barriers in prostate cancer screening: lessons from a volunteer-based MRI screening study.Frontiers in public health · 2025Trial
- Present status of prostate cancer diagnosis, limitations, challenges, and future endeavors.Annals of medicine · 2026Review
- Prostate cancer screening with MRI: insights from the ESUR Prostate MRI Working Group.European radiology · 2026Review
- Contrast-free MRI-first screening in young asymptomatic men: Prostate characteristics and cancer detection rates.Prostate cancer and prostatic diseases · 2026Article
- Association of PI-RADS Score with Clinically Significant Prostate Cancer and Histopathological Upgrading in Patients Undergoing Radical Prostatectomy: A Retrospective Single-Centre Study.Journal of clinical medicine · 2026Article
- Restriction-Weighted Q-Space Trajectory Imaging (ResQ): Toward Mapping Diffusion-Time Effects With Tensor-Valued Diffusion Encoding in Human Prostate Cancer Xenografts.NMR in biomedicine · 2026Article
- Ongoing and completed clinical trials on prostate cancer screening using MRI.European radiology · 2026Review
- Integrating Artificial Intelligence into Prostate MR Imaging: Technical Foundations, Clinical Applications, and Workflow Implications.Magnetic resonance in medical sciences : MRMS : an official journal of Japan Society of Magnetic Resonance in Medicine · 2026Review
- Reply to the Letter to the Editor: Artificial intelligence for prostate MRI screening-methodological considerations regarding reference standards and reader design.European radiology · 2026Article
- Diagnostic accuracy of a 'stage-gated' approach for reporting prostate screening MRI: "Is less more?"European radiology · 2026Article
- Microstructure imaging of prostate cancer by diffusion MRI.Magma (New York, N.Y.) · 2026Review
- Artificial Intelligence for Prognostic Modelling and Adaptive Treatment Monitoring in Radiation Oncology.Cureus · 2026Review
- Primary MRI versus PSA-gated scans in Prostate Cancer Screening - how ready is it for mainstream implementation?Prostate cancer and prostatic diseases · 2026Review
- The Proposed Introduction of a Prostate Cancer Screening Program in Germany: Procedure, Necessary Studies before Implementation, Benefits, and Risks.Deutsches Arzteblatt international · 2026Review
- Prostate Cancer Screening in Contemporary Era: PSA-Based Testing and Risk-Adapted Approaches.Cancers · 2026Review
- Prostate imaging reporting and data system version 2.1 as a predictor of clinically significant and aggressive prostate cancer: a radical prostatectomy-validated study.Translational andrology and urology · 2026Article
- Diagnostic accuracy of abbreviated biparametric MRI for prostate cancer screening: a prospective feasibility study (ReIMAGINE study).European radiology · 2026Article
- Association between amide proton transfer-weighted imaging biomarkers and Gleason score in prostate cancer: a study on differential diagnosis from benign prostatic hyperplasia.Frontiers in oncology · 2026Article
- Analysis of gray zone PSA and PSAD correlated with PIRADS v2.1 in the MRI-US fusion prostate biopsy era: a retrospective bi-centre study.International urology and nephrology · 2025Article
- Overview of Performance Indicators of Prostate Cancer Screening Trials.European urology open science · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesOur objective was to compare prostate cancer detection rates between patients undergoing serum prostate-specific antigen (PSA) vs magnetic resonance imaging (MRI) for prostate cancer screening.
designPhase III open-label randomised controlled trial.
settingSingle tertiary cancer centre in Toronto, Canada.
participantsMen 50 years of age and older with no history of PSA screening for ≥3 years, a negative digital rectal exam and no prior prostate biopsy.
interventionsPatients were recommended to undergo a prostate biopsy if their PSA was ≥2.6 ng/mL (PSA arm) or if they had a PIRADS score of 4 or 5 (MRI arm). Patients underwent an end-of-study PSA in the MRI arm. PRIMARY AND SECONDARY OUTCOME MEASURES: Adenocarcinoma on prostate biopsy. Prostate biopsy rates and the presence of clinically significant prostate cancer were also compared.
resultsA total of 525 patients were randomised, with 266 in the PSA arm and 248 in the MRI arm. Due to challenges with accrual and study execution during the COVID-19 pandemic, the study was terminated early. In the PSA arm, 48 patients had an abnormal PSA and 28 (58%) agreed to undergo a prostate biopsy. In the MRI arm, 25 patients had a PIRADS score of 4 or 5 and 24 (96%) agreed to undergo a biopsy. The relative risk for MRI to recommend a prostate biopsy was 0.52 (95% CI 0.33 to 0.82, p=0.005), compared with PSA. The cancer detection rate for patients in the PSA arm was 29% (8 of 28) vs 63% (15 of 24, p=0.019) in the MRI arm, with a higher proportion of clinically significant cancer detected in the MRI arm (73% vs 50%). The relative risk for detecting cancer and clinically significant with MRI compared with PSA was 1.89 (95% CI 0.82 to 4.38, p=0.14) and 2.77 (95% CI 0.89 to 8.59, p=0.07), respectively.
conclusionsProstate MRI as a stand-alone screening test reduced the rate of prostate biopsy. The number of clinically significant cancers detected was higher in the MRI arm, but this did not reach statistical significance. Due to early termination, the study was underpowered. More patients were willing to follow recommendations for prostate biopsy based on MRI results. TRIAL REGISTRATION NUMBER: NCT02799303.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.